Feb 28, 2023 | Anocca in the news
Originally published in Cell & Gene Therapy Insights Read the transcript of David McCall, Editor, BioInsights speaking to Paula Villaescusa Sánchez, Field Application Specialist, CGT, Cytiva and Anocca’s Head of GMP Process Development, Anette Brass, which...
Dec 16, 2021 | Anocca in the news
Originally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T...
Nov 9, 2021 | Anocca in the news
Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra...
Jul 26, 2021 | Anocca in the news
Originally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies...
Jul 22, 2021 | Anocca in the news
Originally published in BioWorld. DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity...
Jul 22, 2021 | Anocca in the news
Originally published in Scrip. SWEDEN-BASED ANOCCA AB WILL USE A just completed $47m Series B financing to advance its industrialised cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells...
